Table 1.
Antiviral activities of the final compounds 1–4 against HIV type 1 and 2, EMCV, Cox. B3, VSV, and HSV type 1 and 2a
| Compound | MT4b CS50c | HIV (EC50) |
HeLaf CC50g | Anti-RNA (EC50) |
Verok CC50 | Anti-HSV (EC50) |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| IIIBd | RODe | EMCVh | Cox.B3i | VSVj | HSV-1l | HSV-2m | ||||
| 1 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 2 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 3 | >100 | >100 | >100 | 14.54 | >14.54 | >14.54 | 9.43 | >100 | >100 | >100 |
| 4 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| Ribavirin | >300 | 23.45 | 64.09 | 10.32 | ||||||
| ddI | >100 | 6.62 | 16.00 | >10 | 0.17 | 0.47 | ||||
a
The potency is given as an EC50 (50% effective concentration, μg/mL) and evaluated by the degree of inhibition of virus-induced cytopathogenic effects (CPE).
b
HTLV-1-infected human T-lymphocyte.
c
50% cytostatic concentration.
d
Human immunodeficiency virus type 1 strain IIIB.
e
Human immunodeficiency virus type 1 strain ROD.
f
Human cervical carcinoma cell.
g
50% cytotoxic concentration.
h
Encephalomyocarditis virus.
i
Coxsackie B virus type 3.
j
Vesicular stomatitis virus.
k
African Green monkey kidney cell.
l
Herpes simplex virus type 1.
m
Herpes simplex virus type 2.